Enhabit, Inc. (NYSE:EHAB – Get Rating) has received a consensus recommendation of "Hold" from the eight brokerages that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $16.43.

A number of equities research analysts recently weighed in on EHAB shares. Oppenheimer started coverage on shares of Enhabit in a research report on Thursday, October 13th. They issued a "market perform" rating for the company. Stifel Nicolaus initiated coverage on Enhabit in a report on Monday, December 5th. They issued a "buy" rating and a $17.00 target price for the company. UBS Group initiated coverage on Enhabit in a report on Thursday, December 8th. They issued a "sell" rating and a $12.00 target price for the company. CJS Securities initiated coverage on Enhabit in a report on Tuesday, December 13th. They issued a "market perform" rating and a $18.00 target price for the company. Finally, Credit Suisse Group reduced their target price on Enhabit from $19.00 to $15.00 and set a "neutral" rating for the company in a report on Friday, November 4th.

Enhabit Price Performance

Shares of NYSE:EHAB opened at $15.11 on Tuesday. Enhabit has a 52 week low of $11.65 and a 52 week high of $25.25. The company's 50 day moving average is $13.49 and its two-hundred day moving average is $14.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.50 and a quick ratio of 1.50.

Insider Activity

In related news, Director Jeffrey Bolton acquired 2,000 shares of Enhabit stock in a transaction on Wednesday, November 9th. The stock was purchased at an average cost of $12.75 per share, with a total value of $25,500.00. Following the purchase, the director now directly owns 14,597 shares in the company, valued at $186,111.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Jeffrey Bolton acquired 2,000 shares of Enhabit stock in a transaction on Wednesday, November 9th. The stock was purchased at an average cost of $12.75 per share, with a total value of $25,500.00. Following the purchase, the director now directly owns 14,597 shares in the company, valued at $186,111.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gregory S. Rush acquired 8,300 shares of Enhabit stock in a transaction on Monday, November 7th. The shares were bought at an average cost of $12.69 per share, with a total value of $105,327.00. Following the completion of the purchase, the director now owns 16,597 shares in the company, valued at $210,615.93. The disclosure for this purchase can be found here. In the last three months, insiders bought 13,000 shares of company stock valued at $164,903.

Hedge Funds Weigh In On Enhabit

A number of large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Enhabit during the 3rd quarter worth approximately $97,492,000. Vanguard Group Inc. purchased a new position in shares of Enhabit during the 3rd quarter worth approximately $77,886,000. State Street Corp purchased a new position in shares of Enhabit during the 3rd quarter worth approximately $22,827,000. Systematic Financial Management LP purchased a new position in shares of Enhabit during the 3rd quarter worth approximately $20,566,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Enhabit during the 3rd quarter worth approximately $9,662,000. 95.55% of the stock is owned by hedge funds and other institutional investors.

Enhabit Company Profile

(Get Rating)

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Read More

• Get a free copy of the StockNews.com research report on Enhabit (EHAB)
• Is the Worst Behind for Under Armor Stock with a New CEO?
• Analysts Like The Fit Of Skechers USA
• What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
• Can We Trust The Rally In The S&P 500
• Energy Surge: Four Oil-And-Gas Stocks Setting Up In Bullish Bases

Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.